There’s a new sense of excitement surrounding Verve Therapeutics Inc. (VERV)

The closing price of Verve Therapeutics Inc. (NASDAQ: VERV) was $21.59 for the day, up 3.70% from the previous closing price of $20.82. In other words, the price has increased by $+0.77 from its previous closing price. On the day, 597746 shares were traded. VERV stock price reached its highest trading level at $22.08 during the session, while it also had its lowest trading level at $20.65.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…



Our analysis of VERV’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 19.40 and its Current Ratio is at 19.40. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on December 15, 2022, initiated with a Sell rating and assigned the stock a target price of $13.

On October 06, 2022, Credit Suisse started tracking the stock assigning a Neutral rating and target price of $48.

Stifel Upgraded its Hold to Buy on August 25, 2022, whereas the target price for the stock was revised from $32 to $56.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 01 when Bellinger Andrew sold 865 shares for $22.95 per share. The transaction valued at 19,852 led to the insider holds 6,629 shares of the business.

Dorval Allison sold 554 shares of VERV for $12,243 on Nov 29. The Chief Financial Officer now owns 2,186 shares after completing the transaction at $22.10 per share. On Nov 04, another insider, Yeshwant Krishna, who serves as the Director of the company, sold 48,583 shares for $31.14 each. As a result, the insider received 1,512,806 and left with 4,260,047 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 1425.18 while its Price-to-Book (P/B) ratio in mrq is 2.25.

Stock Price History:

Over the past 52 weeks, VERV has reached a high of $43.00, while it has fallen to a 52-week low of $10.70. The 50-Day Moving Average of the stock is 21.51, while the 200-Day Moving Average is calculated to be 24.52.

Shares Statistics:

VERV traded an average of 980.37K shares per day over the past three months and 615.53k shares per day over the past ten days. A total of 57.21M shares are outstanding, with a floating share count of 55.52M. Shares short for VERV as of Oct 13, 2022 were 10.73M with a Short Ratio of 12.47M, compared to 9.86M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 17.90% and a Short% of Float of 33.60%.

Earnings Estimates

The firm’s stock currently is rated by 8 analysts. On average, analysts expect EPS of -$0.74 for the current quarter, with a high estimate of -$0.64 and a low estimate of -$0.87, while EPS last year was -$0.47. The consensus estimate for the next quarter is -$0.74, with high estimates of -$0.63 and low estimates of -$0.87.

Analysts are recommending an EPS of between -$2.74 and -$3.21 for the fiscal current year, implying an average EPS of -$2.95. EPS for the following year is -$2.84, with 7 analysts recommending between -$2.3 and -$3.22.